DYANAVEL XR 20amphetamine, amphetamine aspartate/dextroamphetamine sulfate

FDA approved the original new drug application for DYANAVEL XR 20 on November 4, 2021, sponsored by TRIS PHARMA INC. FDA’s record shows no approved efficacy supplement on the application since.

Application

NDA210526

Sponsor

TRIS PHARMA INC

Original approval

November 4, 2021

Review

standard review

Submission class

Type 3 - New Dosage Form

Active ingredient

amphetamine, amphetamine aspartate/dextroamphetamine sulfate

Browse every approval whose brand starts with D, or the complete response letters FDA has published — the applications it did not approve.

Products under this application

Approved efficacy supplements

An efficacy supplement is how a sponsor asks FDA to approve a change that needs clinical evidence — most often a new indication. FDA’s record gives each one a submission number, a date and a review priority. It does not say what any supplement approved, so neither does this page. The approval letter and label for each are on accessdata.fda.gov under the application number.

FDA’s record shows no approved efficacy supplement on this application.

FDA records other approved supplements on this application, by the class code it assigns them: Labeling 5. Those are changes to the label or to how the drug is made rather than new clinical evidence, so they are counted here and not listed.

Source: FDA’s Drugs@FDA application file, via openFDA (export 2026-09-03). Every field on this page comes from that record.

Other approvals to TRIS PHARMA INC

• May 24, 2024ONYDA XRNDA217645
• October 19, 2015DYANAVEL XRNDA208147
• April 30, 2015TUZISTRA XRNDA207768
• December 3, 2009CLONIDINENDA022499